| INTRODUCTION
The enveloped human immunodeficiency virus type 1 (HIV-1) is a retrovirus capable of penetrating its target cells by fusion of its viral membrane with membranes in the targeted cell.
1 Cellular entry by fusion is preceded by a set of well-characterized interactions involving glycoproteins in the viral envelope, the CD4 receptor and one of the coreceptors CXCR4 or CCR5. [2] [3] [4] [5] [6] [7] The mechanism of interaction of HIV with these receptors is well characterized and leads to specificity of cellular recognition, altered protein conformation, membrane fusion and productive entry to the cell cytoplasm. 8 While the mechanism of fusion is well understood, the specific site of fusion remains controversial. There are 2 primary entry sites: directly from the plasma membrane or from membranes of the endolysosomal system following endocytic uptake of the virus. Alternative entry sites have been explored in a wide range of cell types and one common theme is that productive infection requires the GTPase enzyme dynamin. 18, 21, 24 These studies do not explain how or whether dynamin might play a role at both fusion sites or at additional stages of the virus life cycle.
The majority of observations supporting HIV fusion being dependent on endocytosis have been made largely in HeLa cells. In this cell type evidence is drawn from live single particle viral tracking, the emergence of new generations of potent endocytosis inhibitors targeting either dynamin (herein referred to as dynamin I and dynamin II jointly, since current generation dynamin inhibitors do not discriminate) or clathrin 21, 24, 31 and the use of cell impermeable inhibitors (HIV fusion inhibitors T-20 and C52L).
In CD4 T cells the fusion mechanism is presently controversial, with evidence for or against HIV fusion from within endosomes. For instance, T cell lines can be engineered to express a dominant negative version of dynamin, in turn lacking constitutive endocytosis and yet are still permissive to HIV fusion. 25 In contrast, small molecule dynamin-targeted inhibitors can block both endocytosis and HIV fusion in primary-activated CD4 T cells. 24 Assays that incorporate cell impermeable fusion peptides in cell lines and activated CD4 T cells also show mixed results, with surface accessibility of the HIV fusion reaction (plasma membrane fusion) supported in 1 study 25 and not supported by others. 21, 24 Whilst resting CD4 T cells can also play an important role in HIV persistence, 32 there are no observations at present that define the HIV fusion site in this important HIV target.
One hypothesis emerging from the present controversy of the HIV fusion site, is the regulation of HIV infection by dynamin independent of its role in HIV endocytosis. Alternative and/or additional roles for dynamin in the HIV life cycle are supported by dynamin's multifaceted role in the cell which includes: endocytosis at the plasma membrane, 33 F-actin regulation [34] [35] [36] and cytokinesis at the mid-body during mitosis. 37, 38 Each of these roles has the potential to influence HIV infection through initial endocytosis of the HIV particle, 21 dynamics and influence of F-actin at the cortex [39] [40] [41] [42] [43] [44] and regulation of HIV infection through cell cycle progression. 45 To help resolve inconsistencies with regard to the HIV fusion site in primary CD4 T cells and to further test the hypothesis that HIV entry is dependent on viral particle endocytosis, our broad aim is to gain a mechanistic understanding into how dynamin inhibition influences various stages of the HIV life cycle. The primary focus of our study revolves around 2 major in vivo HIV targets: resting and activated CD4 T cells. As HeLa cell lines have been primarily used in the study of dynamin's influence, we have systematically incorporated them alongside primary T cells.
| RESULTS

| Endocytosis inhibitors block HIV at multiple time points
Our initial aim was to determine the timing of action of dynamin inhibitors during the HIV life cycle. In the time of addition assay the temporal effect of dynamin inhibitors is compared with the effects of well-characterized HIV antiretrovirals on entry, reverse transcription and integration. The time taken for HIV to become refractory to the HIV antivirals serves as time stamp marking completion of that viral event and in turn defines the kinetics of each discrete step in the virus life cycle: ( Figure 1A ). For dynamin inhibition time-of-drugaddition experiments, the small molecule inhibitor dyngo-4a was used because: (1) it has specific activity towards the dynamin helices that are required for endosomal scission 46 ; (2) it was significantly more potent in HIV inhibition than dynasore in initial HeLa cell infections (data not shown). The small molecule clathrin inhibitor pitstop-2 was also used as a control condition to block endocytosis via a different mechanism to dynamin. Together they allow a discrimination of endocytosis from other dynamin functions that are known to not involve clathrin. 31 We initially tested dynamin inhibition in HeLa cell lines engineered to detect HIV infection (TZM-bl) to reproduce published data and then subsequently compared the observations to those in primary CD4 T cells.
Consistent with previous reports, 21, 24 
| Resolution of HIV post-entry blocks mediated by dynamin inhibition
Given the complications of pitstop-2 in primary cells, we consolidated our observations using dynamin inhibition through dyngo-4a. The next series of experiments expanded our time of addition assays to pinpoint any blocks post reverse transcription using detection of HIV DNA in 2 specific states. The first was 2LTR HIV DNA circles that primarily forms within the nucleus and increases if HIV integration is blocked. 48, 49 A decrease in 2LTR DNA post-HIV fusion would support a block in nuclear import, whilst an increase would support a block in integration. Secondly, we detected genomically integrated HIV DNA using Alu-HIV PCR [50] [51] [52] to confirm if HIV has successfully integrated into the human genome. In these assays, we incorporated the HIV integration inhibitor raltegravir as a control.
With the HeLa TZM-bl cell line, 2LTR DNA levels were not significantly lower or higher in the presence of dyngo-4a added at 2 hour post-infection ( Figure 2A , P = .182; n = 4). In contrast the HIV Integrase inhibitor raltegravir significantly increase in 2LTR circles relative to both dimethyl sulfoxide (DMSO) and dyngo-4a treatments (Figure 2A , P = .0044 and P = .0043, respectively; n = 4). This suggests that dynamin does not have a role in the transport across the ) were infected with the CCR5-utilizing HIV-1 Bal strain (B) or activated CD4 T cells with HIV-1 NL43 (C) in the presence of inhibitory compounds added at either 0 or 2 hours post-infection. Data are expressed as mean and SEM and is representative of >3 independent experiments. *P < .05, **P < .01, ***P < .001 compared with relevant DMSO control; unpaired Student's t test. FIGURE 2 Resolution of human immunodeficiency virus (HIV) post-entry blocks through dynamin inhibition. A, Time-of-drug-addition and HIV 2LTR assays in TZM-bl cells (B) and primary activated CD4 T cells after HIV NL43 infections (as described in Fig. 1) . qPCR was performed for HIV DNA 2LTR circles (A-B) to reveal potential blocks of nuclear transport and for HIV integrated DNA (C) to reveal any further blocks in genomic integration. The inhibitors were used at the following concentrations: Maraviroc (10 μM), AZT (10 μM), dyngo-4a (80 μM), AMD3100 (5 μM), Raltegravir (10 μM). Data are representative of in excess of 6 independent experiments. *P < .05, **P < .01, ***P < .001 with respect to relevant dimethyl sulphoxide (DMSO) control; unpaired t test. D-E, Intracellular HIV p24 accumulation an index of productive HIV replication. Resting CD4 T cells were initially infected with NL43 and 2 h later cells were activated and dyngo-4a was added with relevant DMSO controls. At day 3 post infection, cells were permeabilized and stained for intracellular HIV p24. Data are representative of >3 independent experiments. ***P < .001 compared with the relevant DMSO control; unpaired t test. F-H, The effects of dynamin inhibition on the cell cycle in HeLa Fluorescent ubiquitination-based cell cycle indicator (FUCCI) cells (F-G) and activated CD4 T cells (H). In (F-G), the fluorescent cell cycle indicator cells, FUCCI cells, express fluorescent proteins that change from green (mAG fluorescent protein) to red (mKO2 fluorescent protein) throughout key points during the cell cycle detected using flow cytometry for expression of mKO2 (red; 610 nm) and mAG (green; 525 nm). Quantification of discrete stages of the cell cycle in FUCCI cells are presented in several flow cytometry gates. Red populations (mKO2 +ve ) are gated as G1, yellow (mKO2 +ve , We then aimed to resolve why inhibition of dynamin would lead to a HIV transcriptional block. One mechanism of action that is consistent with dynamin inhibition and HIV transcriptional regulation 53 is its action on the cell cycle. Dynamin inhibition is known to directly influence cell cycle progression by arresting late stages of cytokinesis, when dynamin is specifically localized to the mid-body. 54 Similarly, inhibition of clathrin also blocks mitotic progression through its well-known moonlighting role at the mitotic spindle. 31 These mechanisms are consistent with both proteins mediating this post-entry effect. Therefore, the role of cell-cycle influences on HIV transcription was analyzed. In single round TZM-bl HeLa infections, reverse transcription should proceed in the pool of cells at the S-G2-M stage of the cell cycle, 53, 55, 56 as the dNTP pool is increased, permitting efficient reverse transcription. 55, 57 However, later HIV TAT-dependent transcriptional activation requires entry into the G1 stage of the cell cycle. 45 To identify potential changes to the cell cycle in the presence of dyngo-4a the HeLa cell line fluorescent ubiquitination-based cell cycle indicator (FUCCI) was used. These cells express 2 fluorescent protein tags, mKO2 to indicate the G1 phase, Geminin (amino acids 1-120) and Azami-Green 1 (mAG1) to visualize S, G2 and M phases 58 ( Figure 2F ). In unsynchronized FUCCI HeLa cells, dyngo-4a caused cells to accumulate in S-G2-M phase ( Figure 2G ). This is consistent with the hypothesis that the dyngo-4a block in HIV transcription is due to lack of G1 progression and subsequent lack of HIV TAT expression.
We searched for a similar cell-cycle related mechanism in acti- Because HIV initially binds to CD4 on the plasma membrane, and CD4 T cells can also negatively regulate CD4 endocytosis via tethering at the plasma membrane through the lymphocyte specific src kinase Lck, we further observed CD4-specific endocytosis using the 
| HIV kinetics and fusion rates are higher in resting CD4 T cells
To assess whether the rates of endocytosis in activated T cells might increase HIV fusion by the accumulation of virions in endosomal compartments, we next correlated endocytosis rates with HIV fusion rates.
Across independent donors, HIV fusion was consistently higher in resting vs activated T cells ( Figure 4A ; P = .024, which is in stark contrast to the relative endocytic capacities of the 2 cell populations ( Figure 3 ).
The kinetics of early HIV events were then determined using the time taken for 2 distinct entry inhibitors to lose their antiviral activity:
BMS806 blocks the initial envelope CD4 binding 64 and AMD3100
blocks subsequent binding to the chemokine receptor CXCR4. 65 Later stages of HIV fusion, after CD4 and chemokine receptor binding, were blocked by lowering the temperature below 20 C to reveal total fusion kinetics 21, 66 ( Figure 4B ). In measuring the kinetics, our aim was Therefore, endocytosis of HIV is not a limiting step for HIV to initially engage its receptors and complete its fusion reaction in CD4 T cells.
| HIV fusion in resting T cells is primarily at the plasma membrane
The lack of a positive correlation between endocytosis rates and HIV fusion supports a model in which HIV fusion primarily occurs at the plasma membrane in resting CD4 T cells. To directly test this hypothesis,
we determined surface accessibility of the HIV fusion reaction through surface pronase digestion. We focussed on the action of pronase on receptor cell surface accessibility, as stripping proceeds at temperatures that block endocytosis and HIV fusion (schematic presented in Figure 5A ).
As a positive control for this assay, we attempted to use a virus pseudotyped with an endocytosis dependent viral envelope, Vesicular
Stomatitis Virus Glycoprotein (VSVg). Unfortunately, we did not observe any difference in the pronase vs temperature block curves.
Whilst this was initially unexpected, previous studies analyzing the kinetics of VSVg fusion have reported that VSVg mediated fusion occurs within 2 minutes following endocytosis. 67 This process is consistent with our observations as we found that VSVg fusion proceeded almost immediately after the viral particle entered the endosomal network. In contrast, HIV fusion has a lag post receptor This does not support the hypothesis that fusion is dependent on HIV endocytosis and in turn dynamin's role in this latter process.
| Mechanisms that bias HIV fusion to the plasma membrane vs the endosome
In contrast to our observations in resting CD4 T cells, HIV single particle tracking in HIV-HeLa models revealed a bias towards fusion in endosomes. 21, 24 We next determined the mechanisms underpinning with cytoplasmic domain of CD4 68 by preventing CD4 entry into clathrin-coated pits. 69 To determine if Lck expression can tether CD4 at the surface in the face of constitutive endocytosis, Lck was confined to the plasma membrane and that (2) dynamin is specifically involved in the fusion reaction occurring at the plasma membrane. For instance, the IC 50 of dyngo-4a for endocytosis is 5.7 μM, whilst its IC 50 for HIV fusion is 28 μM. Thus, at 10 μM dyngo-4a, cellular endocytosis can be blocked, but HIV fusion and subsequent infection can proceed at levels not significantly different to DMSO vehicle controls.
What might be the mechanism of dynamin's contribution to the HIV fusion reaction? Previous studies proposed a role for dynamin in endocytosis and also HIV pore dilation. 24, 26 Whilst these studies are important, their interpretation was complicated by the cell type and the compound used to modulate dynamin's action. For instance, dynamin's dual influence on endocytosis and HIV fusion at the same rate in HeLa cells led to the conclusion HIV fusion was endocytosis dependent. 21, 24 Compounding this is the use of dynasore, which has the ability to bind different dynamin conformation states and potentially co-influence the dynamics of ring and helical dynamin oligomers. 46 Importantly, our study has enabled the re-interpretation of dynamin's role in HIV fusion by generating clarity at 2 levels: Firstly,
we have demonstrated the role of dynamin in the HIV fusion reaction independent of endocytosis through our data in resting CD4 T cells.
Secondly, we have incorporated well characterized dynamin modulators that preferentially act on distinct dynamin conformations: ryngo-
1-23 by promoting dynamin rings and GTPase activity and dyngo-4a
by inhibiting dynamin helical GTPase activity.
Consolidating our data, we now re-interpret dynamin's role in the fusion reaction. To ensure clarity of dynamin's action we will consider resting CD4 T cells and the timing of action for ryngo-1-23 and dyngo-4a in this setting in the next 2 paragraphs.
Ryngo-1-23 promotes ring formation, ie stimulates dynamin selfoligomerization 34, 35, 80 and in this study it blocks HIV fusion prior to chemokine receptor binding. Dynamin rings have been previously
shown to modulate and increase actin polymerization by displacing the capping protein gelsolin from the barbed ends of actin filaments. 34, 35, 80 The modulation of gelsolin plays a critical role in the F-actin regulation of CD4/chemokine receptor dynamics that increases the probability of chemokine receptor engagement post CD4 binding. Gag and developed as previously described. 81 Transfections for producing viral stocks were done in HEK F293T using polyethylenimine (at 1 mg mL −1 and neutralized to pH 7 [PEI Max, Polysciences]) as described previously. 81, 82 High-titre HIV-1 BaL stocks were propagated in the SupT1-CCR5-CL.30 cell line as described previously. 83 Titering of viral particles was done on TZM-bl cell line as previously described.
83
The TZM-bl line is a derivative of HeLa cells that were engineered by amphotropic retroviral transduction to express CD4 and CCR5, and which were later further engineered using a vector based on HIV-1 to contain Tat-responsive reporter genes for firefly lucifer- Susceptibility of TZM-bl and TZMbl-Lck to HIV infection was quantified by measuring β-galactosidase transcriptional activity as previously described 83 quantification on InCell Investigator (Version 1.6, GE Life Sciences). Dynamin inhibitors dyngo-4a and ryngo-1-23 and the clathrin inhibitor pitstop-2 were synthesized as previously described. 31, 46, 75 All the small molecule inhibitors were resuspended at 30 mM in DMSO and stored for a maximum of 2 months at −80 C. Prior to use, 30 mM stocks were brought to room temperature for 60 minutes and then diluted further to 10 mM with DMSO. At 80 μM of dyngo4a and ryngo-1-23, the final DMSO concentration was 0.8%. All inhibitors were tested for toxicity using Alamar Blue (Thermofisher)
| Inhibitors
under the duration and conditions outlined in each assay. At 80 μM, there was no effect of cellular viability for dyngo-4a and ryngo-1-23.
As mentioned in the results herein there were limitations of using pitstop-2 in primary T cells as the EC 50 was calculated to be 44 μM. 
| Constitutive and CD4-specific endocytosis
| HIV fusion assay
The kinetics of HIV entry into the cytoplasm of CD4 T cells was determined using a Vpr-BlaM fusion assay. Quantification of total HIV-1 DNA was performed as described previously. 86 Primers and locked-nuclei acid probe used were as fol- Quantification of integrated HIV-1 DNA was achieved using a nested PCR protocol to detect Alu-LTR copies, as previously described. 51 First round primers were as follows: Forward Alu primer 5 0 TCC CCA GCT ACT GGG GAG GCT GAG-3 0 and reverse Alu primer 
| Statistical analysis
OriginPro (Version 9.0; Originlab Corporation) was used to perform statistical analyses and generate graphs, unless otherwise specified.
Unless otherwise stated, the data from 2 groups were compared, normal distributions were tested using a Shapiro-Wilk test and for normally distributed data the probability that the mean of each group was significantly different was evaluated using an unpaired Student's t test. For data that is not normally distributed, the probabilities were determined using the Mann-Whitney U test.
